home





























 

















 





















hrsa

participating institutions:
Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital



NEWS AND NEW DEVELOPMENTS



Successful Percutaneous Dihydrotestosterone Treatment of Gynecomastia Occurring during Highly Active Antiretroviral Therapy: Four Cases and a Review of the Literature [Benveniste O et al. CID 2001;33:891] The authors from Paris summarize the world literature on gynecomastia complicating HAART, which includes a total of 14 cases in men and breast hypertrophy in two women. Of these, only four had resolution of the gynecomastia after changes in their HAART regimen. The purpose of the present report is to describe the utility of topical dihydrotestosterone in four men with gynecomastia. These four patients had improvement or resolution of pain and swelling within 10-20 days of initiating topical treatment. The recommendation is 5g/day for 1-3 months.
Comment: Dihydrotestosterone is Androgel, which is available as a 5gm packet and approved for HIV-associated wasting.
posted 10/3/2001





Copyright © 2001-2002. The National AIDS Education and Training Centers Program on behalf of its AETC National Resource Center. All rights reserved.

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.